Novel clot buster to rev­o­lu­tion­ize treat­ment of strokes

BioSpectrum (India) - - SCIENCE NEWS -

A new Clot buster, PEGy­lated Strep­tok­i­nase - a Novel Bi­o­log­i­cal En­tity (NBE) de­vel­oped by Dr Girish Sahni, Di­rec­tor Gen­eral, Coun­cil of Sci­en­tific & In­dus­trial Re­search (CSIR) and Sec­re­tary, Depart­ment of Sci­en­tific and In­dus­trial Re­search (DSIR) and his team of in­ven­tors at CSIRIn­sti­tute of Mi­cro­bial Tech­nol­ogy (CSIR-IMTECH), Chandi­garh is all set to rev­o­lu­tion­ize the treat­ment of is­chemic strokes. Is­chemic stroke is a con­di­tion caused by a dys­func­tion in the sup­ply of blood to the brain due to em­boli, throm­bus or ath­er­o­scle­ro­sis oc­cur­ring in cere­bral ar­ter­ies. CSIR-IMTECH and Epy­gen Biotech Pvt Ltd, Mum­bai, have en­tered into an agree­ment for the lat­ter to de­velop PEGy­lated Strep­tok­i­nase for treat­ment of Is­chemic Stroke. Epy­gen is the first com­pany in In­dia with ex­clu­sive li­cense of this NBE throm­bolytic protein for is­chemic stroke. PEGy­lated Strep­tok­i­nase, the novel re­com­bi­nant protein Throm­bolytic mol­e­cule has been pre­cisely engi­neered through decades of re­search for en­hanced pro­te­olytic sta­bil­ity and ex­tended plasma halflife, fib­rin-speci­ficity and as­so­ci­ated clot speci­ficity, with re­duced im­muno-re­ac­tiv­ity which would be sig­nif­i­cant at­tributes with un­mis­tak­able clin­i­cal ad­van­tages such as re­duced prob­a­bil­ity of hem­or­rhage over cur­rent treat­ment reg­i­mens of throm­bolytic drugs for acute stroke. These are huge ad­van­tages with a po­ten­tial to trans­form the way is­chemic stroke, deep-vein throm­bo­sis, pul­monary em­bolism and acute my­ocar­dial in­farc­tion are treated around the globe, es­pe­cially in the de­vel­op­ing world.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.